Organon (OGN) Short term Debt (2020 - 2026)
Organon (OGN) posted quarterly Short term Debt of $16.0 million for Q1 2026, down 20.0% year-over-year from $20.0 million in Q1 2025, and little changed on a QoQ basis from $16.0 million in Q4 2025.
Organon (OGN) Short term Debt (2020 - 2026) Analysis & Trends
Organon (OGN) has reported Short term Debt for 7 consecutive years, with $16.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Short term Debt fell 20.0% year-over-year to $16.0 million; the TTM figure through Mar 2026 stood at $16.0 million (down 20.0% YoY), while the FY2025 annual figure was $16.0 million, down 20.0% from the prior year.
- Short term Debt came in at $16.0 million for Q1 2026 at Organon, roughly flat from $16.0 million in the prior quarter.
- The five-year high for Short term Debt was $115.0 million in Q2 2025, with the low at $8.0 million in Q3 2022.
- Average Short term Debt over 5 years is $19.2 million, with a median of $9.0 million recorded in 2022.
- Across the five-year window, Short term Debt slumped 99.41% in 2022 and jumped 1177.78% in 2025, its largest moves.
- Year by year, Short term Debt stood at $8.0 million in 2022, then climbed by 12.5% to $9.0 million in 2023, then jumped by 122.22% to $20.0 million in 2024, then retreated by 20.0% to $16.0 million in 2025, then changed by 0.0% to $16.0 million in 2026.
- According to Business Quant data, Short term Debt over the past three periods registered $16.0 million, $16.0 million, and $45.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Organon | 3.53 Bn | 2.41 Bn | 783.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 16.00 Mn |
| Dec 31, 2025 | 16.00 Mn |
| Sep 30, 2025 | 45.00 Mn |
| Jun 30, 2025 | 115.00 Mn |
| Mar 31, 2025 | 20.00 Mn |
| Dec 31, 2024 | 20.00 Mn |
| Sep 30, 2024 | 10.00 Mn |
| Jun 30, 2024 | 9.00 Mn |
| Mar 31, 2024 | 9.00 Mn |
| Dec 31, 2023 | 9.00 Mn |
| Sep 30, 2023 | 8.00 Mn |
| Jun 30, 2023 | 8.00 Mn |
| Mar 31, 2023 | 8.00 Mn |
| Dec 31, 2022 | 8.00 Mn |
| Sep 30, 2022 | 8.00 Mn |
| Jun 30, 2022 | 9.00 Mn |
| Mar 31, 2022 | 9.00 Mn |
| Dec 31, 2021 | 9.00 Mn |
| Sep 30, 2021 | 39.00 Mn |
| Mar 31, 2021 | 1.52 Bn |